Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of cNP8 in healthy adults
NCT06223009Phase 1Completed
- Sponsor
- NeoMatrix Therapeutics
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in burn injury comparing cNP8 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events at Day 8. Started Jan 2024; status: completed.
02
Drugs
cNP8
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT06223009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223009.